• Boehringer Ingelheim GmbH, of Ingelheim, Germany, said a retrospective subanalysis of the 18,113-patient RE-LY trial showed lower rates of intracranial hemorrhage (ICH), including both fatal and traumatic ICH, for Pradaxa (dabigatran etexilate mesylate) capsules 150 mg taken twice daily, compared to warfarin.